Founded in 1999, Dexcom, Inc. (NASDAQ: DXCM), is developing and marketing Continuous Glucose Monitoring (CGM) systems for ambulatory use by people with diabetes and by healthcare providers for the treatment of people with diabetes. The company is the leader in transforming diabetes care and management by providing CGM technology to help patients and healthcare professionals better manage diabetes. Since the company’s inception, Dexcom has focused on better outcomes for patients, caregivers, and clinicians by delivering solutions that are best in class—while empowering the community to take control of diabetes. Dexcom reported full-year 2019 revenue of $1.5B, a growth of 42% versus 2018. Headquartered in San Diego, California, with additional offices in the U.S., Europe, and Asia Pacific, the company employs approximately 5,000 people.